title: Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex.
abstract: Nuclear receptors regulate transcription in direct response to their cognate hormonal ligands. Ligand binding leads to the dissociation of corepressors and the recruitment of coactivators. Many of these factors, acting in large complexes, have emerged as potential chromatin remodelers through intrinsic histone modifying activities. In addition, other ligand-recruited complexes appear to act more directly on the transcriptional apparatus. The DRIP complex is a 15-subunit complex required for nuclear receptor transcriptional activation in vitro. It is recruited to the receptor in response to ligand through specific interactions of one subunit, DRIP205. We present evidence that DRIP205 interacts with another member of the steroid receptor subfamily, estrogen receptor (ER). This interaction occurs in an agonist-stimulated fashion which in turn is inhibited by several ER antagonists. In vivo, a fragment of DRIP205 containing only its receptor interacting region acts to selectively inhibit ER's ability to activate transcription in response to estradiol. These observations suggest a key role for the DRIP coactivator complex in estrogen-ER signaling.
authors.affiliation: Cell Biology Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Cornell University, Graduate School of Medical Sciences, New York, New York 10021, USA.
authors.forename: D
authors.initials: D
authors.lastname: Burakov
authors.forename: C W
authors.initials: CW
authors.lastname: Wong
authors.forename: C
authors.initials: C
authors.lastname: Rachez
authors.forename: B J
authors.initials: BJ
authors.lastname: Cheskis
authors.forename: L P
authors.initials: LP
authors.lastname: Freedman
mesh_terms: D000818:Animals; D019556:COS Cells; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D002460:Cell Line; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D000077267:Fulvestrant; D006801:Humans; D056892:Mediator Complex; D056913:Mediator Complex Subunit 1; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D011485:Protein Binding; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D011960:Receptors, Estrogen / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction; D020349:Surface Plasmon Resonance; D013629:Tamoxifen / Q000494:pharmacology; D015534:Trans-Activators; D014157:Transcription Factors; D015533:Transcriptional Activation / Q000187:drug effects; D014162:Transfection
chemical_list: D002352:Carrier Proteins; C113182:DRIP, VDR interacting protein complex; C538855:MED1 protein, human; C491863:MED4 protein, human; D056892:Mediator Complex; D056913:Mediator Complex Subunit 1; D009687:Nuclear Proteins; D010446:Peptide Fragments; D011960:Receptors, Estrogen; D015534:Trans-Activators; D014157:Transcription Factors; D013629:Tamoxifen; D000077267:Fulvestrant; D020849:Raloxifene Hydrochloride; D004958:Estradiol